Lam Research Corporation stock drops 6% into the weekend: what LRCX traders watch next

Lam Research Corporation stock drops 6% into the weekend: what LRCX traders watch next

New York, Jan 31, 2026, 14:06 EST — The market has closed.

  • Lam Research shares dropped roughly 6% by Friday’s close, following a volatile session.
  • The drop followed just days after a strong earnings report and a forecast that beat expectations.
  • Monday finds investors zeroed in on export-control risks and upcoming data and earnings releases.

Lam Research (LRCX) shares ended Friday down 5.9%, closing at $233.46. The stock swung between a high of $251.90 and a low of $232.28 throughout the session. Trading volume hit roughly 18.4 million shares. (Yahoo Finance)

The decline came just two days after Lam projected third-quarter revenue of $5.7 billion, with a $300 million margin, topping Wall Street forecasts. The company also posted December-quarter results that exceeded expectations. CEO Tim Archer noted, “Entering 2026, our expanding product and services portfolio is enabling the market’s transition to smaller, more complex three-dimensional devices and packages.” (Reuters)

Friday’s move caught attention for that reason. Lam’s outlook is widely viewed as a barometer for chip-equipment spending, especially with memory and advanced packaging demand driving the trend.

The wider market dragged down sentiment, with the S&P 500 dropping 0.43% on Friday. Applied Materials took a bigger hit, sliding 5.57% in that session. (MarketWatch)

Analyst responses were varied, though leaned positive. TD Cowen bumped Lam’s price target sharply to $290 from $170, maintaining its buy rating, Investing.com reported. (Investing)

During the earnings call, Archer told analysts the “AI transformation is driving industry spending higher.” Finance chief Doug Bettinger expects growth “every quarter from the previous quarter” but flagged customer clean-room capacity as a key timing variable. (Investing)

But the risk hasn’t disappeared. In its quarterly filing from Jan. 29, Lam noted that some international sales hinge on export licenses and cautioned that tighter license rules could further shrink demand for its products. The company also revealed that China accounted for roughly 39% of its total revenue in the six months ending Dec. 28, 2025. (QuoteMedia)

Lam provides both GAAP and non-GAAP numbers. The “non-GAAP” figures remove items like stock-based compensation and other adjustments, a format investors frequently rely on to gauge the operating trend.

Monday’s key question: can the stock hold above Friday’s low near $232, after falling short of staying close to $250?

Rates remain in focus this week as traders parse U.S. policy cues following the Federal Reserve’s decision to keep rates unchanged at its recent meeting. (Reuters)

The U.S. January employment report is scheduled for Feb. 6 at 8:30 a.m. ET. Applied Materials will release its results on Feb. 12, while Lam faces scrutiny over whether it can hit its forecasted ranges for the quarter ending March 29. (Bureau of Labor Statistics)

Stock Market Today

  • CSG Share Price Drops 7% Amid Market Uncertainty, Valued Below Fair Price
    January 31, 2026, 4:16 PM EST. CSG (ENXTAM:CSG) shares fell 7% over the past week, closing at €30.56, reflecting cooling momentum. The current price is well below a narrative fair value of €55, based on the company's ammunition focus and defense sector prospects. CSG is a key ammunition supplier for European NATO countries, supporting Ukraine, yet limited public financial data and recent IPO volatility cast uncertainty over valuation. Analyst Marek Trnka highlights assumptions around margins and future earnings multiples influencing this gap. Risks include reduced demand from Ukraine or accelerated peace talks impacting contract visibility. Investors are advised to consider these factors and compare defense sector peers like Rheinmetall before reassessing CSG's market standing.
XLRE price: Real estate stocks hold steady after Warsh Fed pick — what to watch Monday
Previous Story

XLRE price: Real estate stocks hold steady after Warsh Fed pick — what to watch Monday

AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday
Next Story

AstraZeneca share price: $18.5 billion China obesity-drug deal puts AZN stock in focus for Monday

Go toTop